It is conceivable that persistently elevated plasma IL-6 levels promote pancreatic cancer cell survival and a pro-inflammatory tumor microenvironment, and mediate resistance to radiotherapy and chemotherapy, thereby negatively impacting survival of PDAC patients. This evidence concerns the gene IL6 and familial pancreatic carcinoma.